- Home
- Equipment
- north america
- platform prophylactic vaccine
Refine by
Platform Prophylactic Vaccine Equipment Supplied In North America
6 equipment items found
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
Our TCR-antigen discovery capabilities may inform the design and development of next-generation vaccines. Adaptive has validated hundreds of immunogenic antigens that can be selected to design differentiated vaccines. Our platform is also used to detect and track vaccine-induced antigen-specific T cell responses that correlate with efficacy and safety. Our antigen specificity ...
Manufactured by:FluGen, Inc. based inMadison, WISCONSIN (USA)
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen’s flu vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering unprecedented efficacy against infection and illness across seven years of virus drift, and documented steady immune response for at least six ...
Manufactured by:Akshaya Bio Inc. based inEdmonton, ALBERTA (CANADA)
The Chimigen® Platform is a flexible platform vaccine technology designed to elicit both humoral and cellular immune responses in ...
Manufactured by:Angany Inc. based inSt-Jean, QUEBEC (CANADA)
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology. The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight! The fight against allergy is at the heart of ANGANY’s mission. And it is to overcome the specific challenges of allergy that ANGANY has developed a ...
Manufactured by:Tonix Pharmaceuticals Holding Corp. based inChatham, NEW JERSEY (USA)
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
Manufactured by:AIVITA Biomedical, Inc. based in, CALIFORNIA (USA)
AIVITA Biomedical is using its patient-specific vaccine platform to develop a rapidly scalable vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2). AIVITA’s personalized vaccine begins with a basic blood draw, from which the recipient’s own immune cells are extracted and loaded with SARS-CoV-2 antigen. The resulting personalized treatment is designed to create ...